Category: Sci&Tech
Biotech
Pharmaceutical
PopSci
Sci&Tech
Five Takeaways from The Evolving Landscape of Drug Targets
A landmark study by Halip et al. in Nature Reviews Drug Discovery provides a comprehensive, quantitative map of the global drug target landscape. Drawing from DrugCentral data and regulatory review archives, the authors analyze the molecular mechanism-of-action (MoA)...
Pharmaceutical
Sci&Tech
How to use In Vitro Micronucleus Assay in Lead Optimization
You have successfully optimized your lead series to pass the miniaturized Ames screen with flying colors—meaning your molecules are entirely free of bacterial point-mutation liabilities. But when the secondary safety data arrives, a new roadblock emerges:...
Industry
Pharmaceutical
PopSci
Sci&Tech
How traditional drug discovery scientists adapt AI
In recent years, talk about Artificial Intelligence (AI) in drug research has swung between two extremes: people saying AI will cure every disease in months, and people saying it is just a gimmick. For early-stage biotech...
Biotech
Industry
Pharmaceutical
Sci&Tech
The Medchem Strategies in PROTAC Optimization
Proteolysis Targeting Chimeras (PROTACs) have transformed drug discovery by shifting small-molecule therapeutics from an occupancy-driven paradigm (blocking active sites) to an event-driven catalytic mechanism (degrading target proteins). However, translating initial “hitting pairs” into clinical-stage candidates presents unique challenges. Living in...
Pharmaceutical
Sci&Tech
How to Decode and Overcome Ames Mutagenicity in Lead Optimization
In drug discovery, a positive Ames test is an immediate red flag. Because mutagenicity carries an inherent risk of carcinogenicity, regulatory bodies enforce strict guidelines on genotoxic compounds. For a discovery team, a positive Ames result...
GLP
Pharmaceutical
PopSci
Regulation
Sci&Tech
In silico, Chemico, vitro methods: GLP or non-GLP
Good Laboratory Practice (GLP) is a formal regulatory quality system (defined by 21 CFR Part 58 and OECD GLP principles) that governs how nonclinical safety studies are planned, performed, monitored, recorded, archived, and reported. Whether an...
Pharmaceutical
Sci&Tech
How to Navigate and Eliminate hERG Toxicity in Lead Optimization
In drug discovery, hERG channel liability is one of the most common and feared regulatory roadblocks. Because hERG blockage can lead to fatal cardiac arrhythmias, eliminating this specific off-target toxicity is a non-negotiable survival skill for...
Chemical
Pharmaceutical
Sci&Tech
How bench scientist select a reactionsolvent (part-3/end)
When you are pushing a reaction toward a larger pilot-plant scale, or just trying to get enough material for the next stage of testing, you run into the gritty reality of process development: dealing with uncooperative,...
Pharmaceutical
Sci&Tech
How to Solve Metabolic Stability Issues in Early Drug Discovery
You’ve designed a molecule with exceptional oral absorption and carefully tuned its physical chemistry to hit the optimal tissue distribution sweet spot. Yet, when you dose it in a rodent model, the drug’s systemic concentration plummets...
Chemical
Pharmaceutical
Sci&Tech
How bench scientist select a reactionsolvent (part-2)
Once you move past simple substitutions and start building carbon-carbon or carbon-nitrogen bonds, the solvent stops being a passive host and becomes a critical referee. In this phase of process chemistry, your choice of solvent is...